The MPBC Global Alliance Had a Representative Join the 2023 San Antonio Breast Cancer Symposium Virtually and This is What We Learned

The MPBC Global Alliance Had a Representative Join the 2023 San Antonio Breast Cancer Symposium Virtually, and This is What We Learned

 

  • 434531119 1321576968539521 2990451298861294058 n

    Slide 1 - see below for text

  • 433818905 963544518452372 7186172792097529711 n

    Slide 2 - see below for text

  • 434529754 1599288430924755 6671201424578001767 n

    Slide 3 -see below for text

  • 434653519 1361669901085230 6684018334605375192 n

    Slide 4 -see below for text

There were no discussions specific to Metaplastic Breast Cancer.

  • A novel vaccine has been developed that has shown anti-cancer effects in a mouse model of TNBC.
  • Exercise has been shown to slow breast cancer tumor growth and spread in rodent models.
  • Exercise has been shown to improve breast cancer outcomes in observational studies.
  • A large population-based study indicated reduced overall survival if neoadjuvant chemotherapy is applied later than 6 weeks after diagnosis or if adjuvant chemotherapy is applied later than 6 weeks after surgery.

Credit to SABCS 2023 in “Recent advances in triple–negative breast cancer”

Below is the latest information we gained in regards to TNBC:

  • Advances in early-stage TNBC:
    • Adjuvant capecitabine improves disease-free & overall survival
    • Pembrolizumab, in addition to neoadjuvant chemotherapy, improves event-free survival
    • Adjuvantolaparibimproves disease-free & overall survival in gBRCAl/2 mutation-associated high-risk breast cancer
    • Carboplatinaddition to neoadjuvant anthracyclineandtaxanebasedchemotherapy improves disease-free& overall survival
  • Advances in advanced stage TNBC:
    • Olaparib & talazoparib improve progression-free survival in gBRCAl/ mutation-associated breast cancer
    • Pembrolizumab improves progression-free& overall survival in PDLl+ advanced TNBC
    • Sacituzumab govitecan (Trodelvy) improves progression-free & overall survival in pre-treated advanced TNBC
    • Trastuzumab deruxtecan improves progression-free & overall survival in  re-treated advanced HER2 low breast cancer including TNBC”
  • Nearly one-half of breast cancer patients surveyed reported significant financial burden due to breast cancer
  • Regional nodal irradiation after neoadjuvant chemotherapy and breast cancer surgery does not improve overall survival, according to a study

MpBC Global Alliance Inc. Key Takeaways:

Continue to focus on gaining more research and attention specific to Metaplastic Breast Cancer without lumping us into TNBC.

Future Goals:

Support a conference/symposium specific to MpBC.

Sources:

Telli, M. (n.d.). San Antonio Breast Cancer Symposium

2023. In recent advances in triple-negative breast cancer. San Antonio.

Leon-Letelier, R. (n.d.). San Antonio Breast Cancer Symposium 2023. In a novel citrullinated-ENOl-peptide­ based vaccine for triple-negative breast cancer prevention.

Chino, F. (n.d.). San Antonio Breast Cancer Symposium

2023. In Patient-Reported Benefits of Resources Designed to Assist With the Financial Toxicity of Breast Cancer.

Courneya, K. (n.d.). San Antonio Breast Cancer Symposium

2023. In Im act of Exercise on Breast Cancer Outcomes